Korean J Med.  2018 Oct;93(5):439-446. 10.3904/kjm.2018.93.5.439.

Antimicrobial Therapy for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria

Affiliations
  • 1Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea. collacin@hotmail.com

Abstract

Carbapenem-resistance emerging in Gram-negative pathogens, such as Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, has become a major human health problem globally. The therapeutic options available for carbapenem-resistant pathogens are very limited. Antibiotics such as colistin, tigecycline, fosfomycin, and aminoglycosides are often the only ones that can be used to treat carbapenem-resistant pathogens. Carbapenem may still be an option in certain circumstances. The administration of combination therapy for carbapenem-resistant pathogens is controversial. This review presents the current knowledge of available antimicrobial therapeutic options for infections due to carbapenem-resistant pathogens in Korea.

Keyword

Gram-negative bacteria; Carbapenem; Drug resistance; Treatment outcome

MeSH Terms

Acinetobacter baumannii
Aminoglycosides
Anti-Bacterial Agents
Colistin
Drug Resistance
Fosfomycin
Gram-Negative Bacteria*
Humans
Klebsiella pneumoniae
Korea
Pseudomonas aeruginosa
Treatment Outcome
Aminoglycosides
Anti-Bacterial Agents
Colistin
Fosfomycin
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr